Serious respiratory infections can increase clozapine levels and contribute to side effects: A case report

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 6, 2003, Pages 1059-1063

  De Leon, Jose ^a,b   Diaz, Francisco J ^a,c  

^a Eastern State Hospital   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Clozapine; Cytochrome P450 1A2; Infections; Metabolism

Indexed keywords

AMOXICILLIN; ATORVASTATIN; BENZATROPINE; CLAVULANATE POTASSIUM; CLOZAPINE; DOCUSATE SODIUM; GEMFIBROZIL; NEUROLEPTIC AGENT; NORCLOZAPINE; OLANZAPINE; PENICILLIN V POTASSIUM; PROPRANOLOL; PSEUDOEPHEDRINE; QUETIAPINE; RISPERIDONE; SORBITOL; VALPROIC ACID; ZIPRASIDONE;

ADULT; AKATHISIA; ARTICLE; CALCULATION; CASE REPORT; CLINICAL PRACTICE; CONSTIPATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LEG FOLDING; MALE; MYOCLONUS; NOISE MEASUREMENT; RESPIRATORY TRACT INFECTION; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; TREMOR;

EID: 0141851847     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00148-9     Document Type: Article

References (28)

1. Abdel-Razzak Z., Loyer P., Fautrel A., Gautier J.C., Corcos L., Turlin B., Beaune P., Guillouzo A. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol. Pharmacol. 44:1993;707-715.
2. Antelo R.E., Stanilla J.K., Martin-Lloch N. Myoclonic seizures and "leg folding" with clozapine therapy: report of two cases. Biol. Psychiatry. 36:1994;759-762.
3. Benet L.Z., Hoener B. Changes in plasma protein binding have little clinical significance. Clin. Pharmacol. Ther. 71:2002;115-121.
4. Bertilsson L., Carrillo J.A., Dahl M., Llerena A., Alm C., Bondesson U., Lindstrom L., de la Rubia I.R., Ramos S., Benitez J. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol. 38:1994;471-473.
5. Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:1997;210-258.
6. Buur-Rasmussen B., Brosen K. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur. Neuropsychopharmacol. 9:1999;453-459.
7. Callaghan J.T., Bergstrom R.F., Ptak L.R., Beasley C.M. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 37:1999;177-193.
8. Carrillo J.A., Herraiz A.G., Ramos S.I., Benitez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J. Clin. Psychopharmacol. 18:1998;311-316.
9. Chang K.C., Bell T.D., Lauer B.A., Chai H. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet. 1:1978;1132-1133.
10. de Leon J. Glucuronidation enzyme genes and psychiatry. Int. J. Neuropsychopharmacol. 6:2003;57-72.
11. de Leon J., Henighan V., Stanilla J.K., Simpson G.M. Clozapine levels after clozapine discontinuation (letter). J. Clin. Psychopharmacol. 16:1996;193-194.
12. de Leon J., Diaz F.J., Rogers T., Browne D., Dinsmore L., Ghosheh O., Dwoskin L.P., Crooks P. A pilot study of plasma caffeine concentrations in a US sample of smokers and non-smokers volunteers. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 27:2003;165-171.
13. DeVane C.L. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacol. Bull. 36:2002;5-21.
14. Hasegawa M., Gutierrez-Esteinou R., Way L., Meltzer H.Y. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J. Clin. Psychopharmacol. 13:1993;383-390.
15. Hughes J.R., Liguori A., Dominick A., MacLaughlin M. Effects of smoking abstinence on the subjective effects of caffeine. Nicotine Tob. Res. 1:1999;229-232.
16. McCarthy R.H. Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry. 27:1994;210-211.
17. Odom-White A., de Leon J. Clozapine levels and caffeine (letter). J Clin. Psychiatry. 57:1996;175-176.
18. Olesen O.V. Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations. Clin. Pharmacokinet. 34:1998;497-502.
19. Ozdemir V., Kalow W., Posner P., Collins E.J., Kennedy J.L., Tang B., Albers L.J., Reist C., Roy R., Walkes W., Afra P. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia. J. Clin. Psychopharmacol. 21:2002;398-407.
20. Perry P.J., Miller D.D., Arndt S.V., Cadoret R.J. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenia patients. Am. J. Psychiatry. 148:1991;231-235.
21. Pinninti N.R., de Leon J. Interaction of sertraline with clozapine (letter). J. Clin. Psychopharmacol. 17:1997;119-120.
22. Potkin S.G., Bera R., Gulaskaram B., Costa J., Hayes S., Jin Y., Richmond G., Carreon D., Sitanggan K., Gerber B., Telfold J., Plon L., Plon H., Park L., Chang J.J., Oldroyd J., Cooper T. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J. Clin. Psychiatry. 55(Sept. Suppl. B):1994;133-136.
23. Raaska K., Raitasuo V., Arstila M., Neuvonen P.J. Bacterial pneumonia can increase serum concentration of clozapine. Eur. J. Clin. Pharmacol. 58:2002;321-322.
24. Shilalukey K., Robieux I., Spino M., Greenwald M., Shear N., Koren G. Are current pediatric dose recommendations for intravenous theophylline appropriate? J. Asthma. 30:1993;109-121.
25. Simpson G.M., Cooper T.A. Clozapine plasma levels and convulsions. Am. J. Psychiatry. 135:1978;99-100.
26. Simpson G.M., Josiassen R.C., Stanilla J.K., de Leon J., Nair C., Abraham G., Odom-White A., Turner R.M. Double-blind study of clozapine dose response in chronic schizophrenia. Am. J. Psychiatry. 156:1999;1744-1750.
27. Skogh E., Bengtssson F., Nordin C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther. Drug Monit. 21:1994;580-582.
28. Zullino D.F., Delessert D., Eap C.B., Preisig M., Baumann P. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int. Clin. Psychopharmacol. 17:2002;141-143.